Jean-Paul Clozel, Idorsia CEO (Patrick Straub/Keystone via AP Images)
September 6, 2023 06:47 AM EDT
Deals
FDA+

Amid aproci­ten­tan’s reg­u­la­to­ry re­view, Idor­sia is buy­ing back the hy­per­ten­sion drug from J&J in $350M deal

Reynald Castañeda

Deputy Editor

John­son & John­son’s Janssen is hand­ing back the glob­al de­vel­op­ment and com­mer­cial­iza­tion rights to the hy­per­ten­sion can­di­date aproci­ten­tan to Idor­sia. This …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Law­mak­ers are pok­ing holes in phar­ma's fa­vorite new way to mar­ket med­i­cines

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times